FDA’s advisory committee has endorsed Truqap plus abiraterone and ADT as a treatment option with a favorable benefit-risk ...

An FDA advisory panel voted 7-1, with one abstention, to endorse AstraZeneca’s capivasertib plus abiraterone and ADT for PTEN-deficient metastatic hormone-sensitive prostate cancer. The CAPItello-281 ...

Mark Stein, MD, explores managing mHSPC through PSMA PET imaging, tumor burden assessment, and AMPLITUDE trial data while considering clinical context. The widespread adoption of PSMA PET imaging has ...

An FDA advisory committee has recommended expanding AstraZeneca’s capivasertib for use with abiraterone and prednisone in PTEN-deficient metastatic hormone-sensitive prostate cancer. The 7-1 vote, ...

Oncologic Drugs Advisory Committee (ODAC) has recognized a favorable benefit risk profile for AstraZeneca's TRUQAP® (capivasertib) in combination with abiraterone and androgen deprivation therapy (ADT ...

From AI-powered scam detection to data removal and remote access blocking, here are the best tools to help protect your ...

The first GameSir G8 was an affordable return to iPhone grip controllers, and while its successor doesn't have any significant bells or whistles, it gains Apple certification and iPad mini support.

Federal authorities have seized millions of dollars from a Pasadena clinic suspected of bilking Medicare in a skin graft ...

Israeli Prime Minister Benjamin Netanyahu on Friday announced that his medical report was released, and that he had been ...

Delve into the field of PARP inhibitors, a class that has gained traction in ovarian, breast, and prostate cancers.

Biochemical recurrence after radiotherapy is common and clinically challenging in prostate cancer (PCa), as accurate restaging is required to identify patients eligible for local salvage therapy and ...